Rituximab limits glucocorticoid use in IgG4-related disease: Real-world evidence from a large European cohort
{{output}}
Objectives: While glucocorticoids have been considered the standard of care for IgG4-related disease (IgG4-RD), rituximab is increasingly used off-label. We aimed to evaluate the glucocorticoid-sparing ability of rituximab using ... ...
